Stockscreener 앱 받기
4.42
4.25%
0.18
전일 마감가:
$4.24
열려 있는:
$4.24
하루 거래량:
120
Relative Volume:
0.00
시가총액:
$98.55M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.23%
1개월 성능:
-19.93%
6개월 성능:
-48.18%
1년 성능:
-42.82%
1일 변동 폭
$4.24
$4.24
1주일 범위
$4.04
$4.43
52주 변동 폭
$4.04
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
명칭
Actuate Therapeutics Inc
전화
847-986-4190
주소
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
4.24 | 98.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.70 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.52 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
837.58 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.03 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.27 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-26 | 개시 | B. Riley Securities | Buy |
| 2025-04-22 | 개시 | Craig Hallum | Buy |
| 2025-03-17 | 개시 | H.C. Wainwright | Buy |
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6%Here's What Happened - MarketBeat
What is the long term forecast for GATES GROUP Inc. stockJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Published on: 2026-02-07 16:03:44 - baoquankhu1.vn
Actuate Therapeutics registers 1.33M shares for resale by investors - MSN
Patterns Watch: Is Actuate Therapeutics Inc benefiting from innovation trendsJuly 2025 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Decliners Report: Is Actuate Therapeutics Inc benefiting from innovation trendsBreakout Watch & Daily Profit Maximizing Tips - baoquankhu1.vn
Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics - Clinical Leader
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt - Yahoo Finance
Sectors Review: Will Actuate Therapeutics Inc stock benefit from M AJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Actuate Therapeutics plans phase 1/2 trial of oral cancer drug - Investing.com Nigeria
Aug EndMonth: Whats the beta of PHGE stockJuly 2025 Chart Watch & Verified Entry Point Detection - baoquankhu1.vn
Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers - manilatimes.net
Actuate Therapeutics Announces Plans to Expand Clinical - GlobeNewswire
Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest - MarketBeat
Risk Report: Why is VNCE stock going down2025 Technical Patterns & Detailed Earnings Play Strategies - baoquankhu1.vn
Merger Talk: Is Actuate Therapeutics Inc stock undervalued right nowInflation Watch & Fast Moving Stock Trade Plans - baoquankhu1.vn
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to “Sell” - Defense World
Is Actuate Therapeutics Inc stock showing strong momentumPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum - The Globe and Mail
Market Wrap: Does Actuate Therapeutics Inc have consistent dividend growth2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Published on: 2026-01-16 10:23:54 - baoquankhu1.vn
Published on: 2026-01-16 07:35:07 - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Actuate Therapeutics stock at $20 - Investing.com UK
Price Action: Is Actuate Therapeutics Inc stock risky to hold nowPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Quarterly Recap: Can Actuate Therapeutics Inc stock deliver consistent earnings growthJuly 2025 WrapUp & Smart Money Movement Tracker - Bộ Nội Vụ
Actuate Therapeutics reports positive Phase 2 pancreatic cancer data - TipRanks
Actuate Therapeutics IncReports positive phase 2 trial data for elraglusibSEC filing - marketscreener.com
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Actuate Therapeutics Reports Positive Phase 2 Study Results for Elraglusib Combination in Metastatic Pancreatic Cancer - Quiver Quantitative
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at AS - GlobeNewswire
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ... - Sahm
Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Will Actuate Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Why Actuate Therapeutics Inc. stock is recommended by analysts2025 Pullback Review & Weekly Return Optimization Alerts - Улправда
Can Actuate Therapeutics Inc. stock sustain market leadershipJuly 2025 Final Week & Weekly Breakout Watchlists - Улправда
Insider at Actuate Therapeutics Makes a Major Move With Fresh Stock Sale - TipRanks
Actuate therapeutics director Kairos Venture Partners II, L.P. sells $1.6m in shares - Investing.com Nigeria
Actuate Therapeutics Insider Sold Shares Worth $1,624,000, According to a Recent SEC Filing - marketscreener.com
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results - Investing.com Canada
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results By Investing.com - Investing.com South Africa
Actuate Therapeutics stock rises on positive pediatric cancer trial data By Investing.com - Investing.com Nigeria
Actuate Therapeutics stock rises on positive pediatric cancer trial data - Investing.com
Actuate Therapeutics Reports Promising Initial Clinical Responses in Pediatric Cancers from Phase 1 Trial of Elraglusib - Quiver Quantitative
Experimental drug shrinks tough childhood tumors in early trial - Stock Titan
Analyst Downgrade: Is Actuate Therapeutics Inc stock supported by innovation pipelineTrade Performance Summary & Daily Profit Focused Stock Screening - moha.gov.vn
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher – Here’s What Happened - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% HigherHere's What Happened - MarketBeat
Can Actuate Therapeutics' Elraglusib Overcome The Hurdles Of GSK-3ß Inhibition? - RTTNews
Actuate Therapeutics Inc (ACTU) 재무 분석
Actuate Therapeutics Inc (ACTU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.86%
0.22%
자본화:
|
볼륨(24시간):